Cesca Therapeutics (KOOL) is Downgraded by Maxim Group to Hold , according to the research report released to the investors. Earlier the firm had a rating of Buy on the company shares. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.
Shares of Cesca Therapeutics Inc. (NASDAQ:KOOL) ended Thursday session in red amid volatile trading. The shares closed down 0.0422 points or 15.06% at $0.238 with 573,969 shares getting traded. Post opening the session at $0.28, the shares hit an intraday low of $0.2213 and an intraday high of $0.28 and the price vacillated in this range throughout the day. The company has a market cap of $9.7 million and the number of outstanding shares has been calculated to be 40,673,265 shares. The 52-week high of Cesca Therapeutics Inc. (NASDAQ:KOOL) is $1.14 and the 52-week low is $0.26.
During the last several months other analysts have commented on the company rating. H.C. Wainwright assumes its rating on Cesca Therapeutics Inc. (NASDAQ:KOOL). The global brokerage major announces a current price target of $2 per share. Analysts at the H.C. Wainwright have a current rating of Buy on the shares. The rating by the firm was issued on September 21, 2015.
Cesca Therapeutics Inc. (NASDAQ:KOOL) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1 from 2 analysts. 2 have rated it as a strong buy.
Cesca Therapeutics Inc. (NASDAQ:KOOL): 2 Analyst have given the stock of Cesca Therapeutics Inc. (NASDAQ:KOOL) a near short term price target of $1.5. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.71. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.
Cesca Therapeutics Inc. has lost 37.37% in the last five trading days and dropped 20.67% in the last 4 weeks. Cesca Therapeutics Inc. has dropped 64.48% during the last 3-month period . Year-to-Date the stock performance stands at -76.67%.
Cesca Therapeutics Inc, formerly ThermoGenesis Corp., designs, develops and commercializes devices and disposable tools for the processing, storage and administration of cell and tissue therapies used in the practice of regenerative medicine. The Company’s products automate the volume reduction and cryopreservation of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. The Company provides products and technologies to enables cell separation, processing and cryopreservation for storage of biological fluids, including umbilical cord blood, peripheral blood and bone marrow in a format. In February 2014, the Company consummated the merger with TotipotentRX Corporation.